Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460375 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
A Phase 1 study, sponsored by LigaChem Biosciences.
- Not yet
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
NCT07460375: Clinical Trial Phase 1 study, sponsored by LigaChem Biosciences.
NCT07460375 is a Phase 1 study that has not yet begun recruiting, run by LigaChem Biosciences. The registered enrollment target is 191 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07460375, a Phase 1 study, has not yet begun recruiting, sponsored by LigaChem Biosciences.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
Study Summary
This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.
Primary Outcome
Incidence and severity of AEs
Interventions
- DRUG LCB02A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
What is known before NCT07460375 opens enrollment
NCT07460375 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (218% higher).
The record links to 0 conditions, and to 1 intervention - of which LCB02A is the first listed.
NCT07460375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07460375 about?
NCT07460375 is a clinical study titled "A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors". This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options ar...
What is the current status of trial NCT07460375?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07460375?
The interventions under investigation include: LCB02A (DRUG).
Who is sponsoring clinical trial NCT07460375?
This trial is sponsored by LigaChem Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07460375's enrollment target sits among peer trials
191 283rd of 2000 higher than 1,717 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia